Inventage Lab, a South Korean biopharmaceutical company, has acquired a 40% stake and management rights in South Korean vaccine developer, Quratis.

Inventage Lab’s will integrate its IV-DrugFluidic platform with Quratis’ GMP-certified Osong Bio Plant to enhance clinical and commercial manufacturing, while Quratis will use the funds to expand its CDMO services.